Close Menu

NEW YORK – Siemens Healthineers said Monday that its fiscal year 2020 first quarter revenues were up 9 percent year over year. On a comparable basis, the firm posted a year-over-year revenue increase of 6 percent.

The firm also announced Monday that it has inked a contract to become the primary supplier of products for immunoassay testing to Secaucus, New Jersey-based Quest Diagnostics.

For the three months ended Dec. 31, 2019, Siemens Healthineers reported total Q1 revenues of €3.59 billion ($3.97 billion), up from €3.30 billion in the prior-year quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.